TABLE 5.
Mean hematological values before treatment, following the 10-week antiviral efficacy study with MIV-210 given daily at 20 mg/kg or 60 mg/kg, and at the end of the 10-week follow-up period after the cessation of treatment
| Treatment groupa and parameter (unit of measurement) | Value (mean ± SEM)
|
||
|---|---|---|---|
| Wk 0 (before treatment) | Treatment wk 10 | After the 10-wk follow-upb | |
| Placebo | |||
| HCT (%) | 40.0 ± 2.6 | 36.4 ± 4.7 | 36.1 ± 3.1 |
| HGB (g/dl) | 13.6 ± 1.3 | 12.5 ± 3.4 | 12.3 ± 1.1 |
| WBC (109/liter) | 8.7 ± 1.8 | 6.2 ± 1.2 | 5.5 ± 1.2* |
| Grans (109/liter) | 8.8 ± 3.3 | 6.7 ± 2.7 | 6.7 ± 2.0 |
| L/M (109/liter) | 4.7 ± 2.4 | 2.6 ± 0.9 | 2.2 ± 0.4 |
| PLT (109/liter) | 408.8 ± 188 | 431.4 ± 127.6 | 441.7 ± 118.8 |
| MIV-210 at 20 mg/kg/day | |||
| HCT (%) | 44.1 ± 3.0 | 37.3 ± 6.1 | 37.3 ± 4.8*** |
| HGB (g/dl) | 14.5 ± 1.2 | 12.7 ± 5.0 | 12.7 ± 1.7 |
| WBC (109/liter) | 11.8 ± 2.9 | 11.5 ± 5.3 | 7.2 ± 1.6** |
| Grans (109/liter) | 11.6 ± 4.1 | 12.1 ± 6.4 | 7.4 ± 2.2** |
| L/M (109/liter) | 9.9 ± 4.1 | 5.1 ± 3.5 | 4.4 ± 1.9** |
| PLT (109/liter) | 338.8 ± 119.4 | 509 ± 152 | 400 ± 68.7c |
| MIV-210 at 60 mg/kg/day | |||
| HCT (%) | 47.1 ± 7.1 | 36.7 ± 5.2 | 35.3 ± 4.9* |
| HGB (g/dl) | 15.2 ± 1.8 | 12.4 ± 1.6 | 12.2 ± 1.7 |
| WBC (109/liter) | 13.5 ± 5.5 | 6.3 ± 1.7 | 7.0 ± 1.8 |
| Grans (109/liter) | 15.7 ± 8.0 | 6.3 ± 2.7 | 6.9 ± 2.7 |
| L/M (109/liter) | 10.0 ± 7.0 | 3.1 ± 1.3 | 3.5 ± 2.2 |
| PLT (109/liter) | 465.8 ± 102.7 | 393.4 ± 155.6 | 404.3 ± 78.6 |
In all groups, there were six animals before treatment and five animals at treatment week 10. At the end of the 10-week follow-up, there were four animals in the placebo group, five animals in the group receiving MIV-210 at 20 mg/kg/day, and six animals in the group receiving MIV-210 at 60 mg/kg/day.
Asterisks indicate that the differences between mean values calculated for individual hematological parameters after the 10-week follow-up and those obtained prior to treatment (week zero) were significant at P values of ≤0.008 (***), ≤0.02 (**), or ≤0.05 (*). No significant differences were found between the placebo-treated and MIV-210-treated animals at the end of the 10-week treatment period.
For this measurement, n = 4.